MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
1.160
+0.020
+1.75%
Closed 19:40 12/19 EST
OPEN
1.170
PREV CLOSE
1.140
HIGH
1.190
LOW
1.140
VOLUME
71.78K
TURNOVER
32.22K
52 WEEK HIGH
10.96
52 WEEK LOW
1.081
MARKET CAP
4.11M
P/E (TTM)
-0.1825
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at ENSC last week (1208-1212)?
Weekly Report · 12/15 10:44
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/09 17:05
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation
Benzinga · 12/09 16:09
Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614
TipRanks · 12/09 13:25
Ensysce Biosciences Launches Phase 3 Trial of Abuse-Resistant Opioid PF614
Reuters · 12/09 13:00
Weekly Report: what happened at ENSC last week (1201-1205)?
Weekly Report · 12/08 10:42
Ensysce Biosciences files to sell 4.6M shares of common stock for holders
TipRanks · 12/02 22:00
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.